Biotech | January 05, 2022
Biogen exercises option with Ionis for spinal muscular atrophy
Biogen paid Ionis a US $ 60 million one-time upfront payment
Biogen paid Ionis a US $ 60 million one-time upfront payment
It is a novel oral NLRP3 inflammasome inhibitor
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
Klifovet’s client base comprises the world’s top animal health and nutrition companies as well as many promising startups
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
Subscribe To Our Newsletter & Stay Updated
